Home

Annalisa Jenkins

CIK 1639481 · President and CEO · last filed 2026-04-02

Annalisa Jenkins is a President and CEO who has filed 38 SEC Form 4 insider transactions across 8 companies since 2015. Across all open-market trades the lifetime net is −$42.2K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $399.4K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$399.4K

Companies

8

Total Filings

38

Lifetime Open-Market Net

-$42.2K

Filer Profile

Reported Address
C/O ARDELYX, INC.
34715 ARDENWOOD BLVD, SUITE 100
FREMONT, CA 94555
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
SKYE Director — $2.04 — $0 4 2026-04-02
MREO Director — $0.28 — $0 3 2026-02-27
CMPS Director 19,480 $14.35 $279.5K -$42.2K 11 2025-06-13
Tectonic Therapeutic, Inc. (AVRO) Delisted Director — $16.80 — $0 5 2023-06-08
Serina Therapeutics, Inc. (AGE) Delisted Director — $11.10 — $0 2 2021-06-23
ARDX Director 33,471 $3.58 $119.8K $0 5 2019-06-17
Dimension Therapeutics, Inc. (DMTX) Delisted President and CEO — — — $0 4 2017-11-07
ONCOSEC MEDICAL Inc (ONCS) Delisted Director — $0.28 — $0 1 2017-09-05

Recent Filings

38 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-10 — Notice (144) −26,000 -$345.8K EDGAR
2026-08-07 — Notice (144) −83,771 -$1.15M EDGAR
2026-04-02 SKYE Grant (A) — $0 EDGAR
2026-02-27 MREO Grant (A) — $0 EDGAR
2026-02-09 SKYE Grant (A) — $0 EDGAR
2025-06-13 CMPS Grant (A) — $0 EDGAR
2025-02-26 SKYE Grant (A) — $0 EDGAR
2025-02-06 MREO Grant (A) — $0 EDGAR
2024-10-30 SKYE Grant (A) — $0 EDGAR
2024-08-05 CMPS Tax (F) −161 -$1.1K EDGAR
Showing 1–10 of 38
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.